Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)

• Published in: Journal of oncology pharmacy practice Vol. 26; no. 7; p. 1583
• Main Authors: Hizal, Mutlu, Sendur, Mehmet An, Yasar, Hatime Arzu, Bir Yucel, Kadriye, Arslan, Cagatay, Ucar, Gokhan, Karakaya, Serdar, Taban, Hakan, Kucukarda, Ahmet, Erturk, Ismail, Bilgin, Burak, Yıldırım, Nuriye, Demirci, Umut, Kılıckap, Saadettin, Cicin, Irfan, Karadurmus, Nuri, Yalcin, Bulent, Ürün, Yüksel
• Format: Journal Article
• Language: English
• Published: England 01.10.2020
• Subjects: Carcinoma, Renal Cell - mortality; Carcinoma, Renal Cell - pathology; Female; Humans; Kidney Neoplasms - pathology; Lymphocytes - metabolism; Male; Middle Aged; Neutrophils - metabolism; Prognosis; Retrospective Studies; tyrosine kinase inhibitors; Interferon; renal cell cancer; neutrophil–lymphocyte ratio; prognosis
• ISSN: 1477-092X
• DOI: 10.1177/1078155219900908

To describe the prognostic value of neutrophil-lymphocyte ratio and its effect on survival in in patients with advanced renal cell carcinoma. We retrospectively analyzed 331 patients. The cut-off value of neutrophil-lymphocyte ratio was specified as "3" which is mostly close-and also clinically easily applicable-to the median neutrophil-lymphocyte ratio level of our study group. High group is identified as neutrophil-lymphocyte ratio >3 (n = 160) and low group is identified as neutrophil-lymphocyte ratio ≤3 (n = 163). A total of 331 (with 211 male and 120 female) patients were enrolled to study. The median age of the patients was 58. The International Metastatic RCC Database Consortium risk score is calculated for the 72.8% (n = 241) of the study group and among these patients, favorable, intermediate, and poor risk rates were 22, 45.2, and 32.8%. The total usage of tyrosine kinase inhibitors reached 78% of the patients. The median overall survival was 32 months versus 11 months in the neutrophil-lymphocyte ratio low and high groups, respectively (HR: 0.49 (95% CI 0.37-0.65), p < 0.001). In conclusion, the pre-treatment value of elevated neutrophil-lymphocyte ratio might be a predictor of poor overall survival in advanced renal cell carcinoma patients.